Page 67 - Sohini Das

Price rationalisation, consolidation likely in Indian diagnostic space

Competitive pricing, however, is here to stay, feel analysts and some industry insiders

WTO's vaccine patent waiver may have little impact on ground now: Industry

Serum Institute says while patent waivers for Covid-19 vaccines are 'encouraging', demand for vaccines today is declining

Bharat Biotech's Covaxin is safe for children between 2 and 18 yrs: Lancet

Data from over 50 million doses reveals minimal side effects

Glenmark drug for treating uncontrolled asthma gets Indian regulator's nod

Company says treatment will be affordable and improve lung function of patients

Top 300 drug brands to have QR codes on label for ensuring authenticity

The Union Ministry of Health has made amendments to the Drugs Rules, 1945, to implement this

Vaccine makers claims efficacy against Omicron variant of Covid-19

Omicron has been the dominant strain across the world since January, quickly replacing the Delta variant that had caused a devastating second wave in India

Lots of interest in Metropolis, but we want a strategic fit: MD Ameera Shah

In a Q&A, the promoter and MD of the company talks about how the dynamics are changing in the diagnostics sector post Covid, and outlines her strategy for Metropolis 3.0

No plans to exit business, says Metropolis Healthcare promoters

"The company, its promoters and management team are committed to operating Metropolis Healthcare Ltd with the highest standards of medical science, stakeholder trust and customer engagement," the comp

No plans to exit business, clarify Metropolis Healthcare promoters

Metropolis Healthcare is continuously exploring various strategic options and investment

Corbevax gets approval as heterogenous vax, but isn't listed on CoWin

Company had issued a press release on June 4 where it said DCGI has approved Corbevax as a heterologous Covid booster dose to individuals aged 18 and above after 6 months of primary vaccination

Hundreds of millions of Covid vaccines in India to expire in September

Covaxin has a shelf life of 12 months, while Covishield, the vaccine that accounted for nearly 80% of India's vaccinations, has a shelf life of nine months

Gene therapy to cure leukemia at one-tenth global costs in the works

ImmunoACT, backed by Laurus Labs is testing their cancer product

Mumbai amps up hospital capacity and stocks medicines as Covid cases rise

Occupancy has more than doubled over the last week

Covid-19 testing drops even as daily cases rise to three-month high

Testing volumes have not grown much nationally, though individual states show some improvement

India's Serum Institute to make Novavax's Covid vaccine for US market

The company has indicated in the first quarter earnings call that it has reached a major milestone in its pathway to an emergency use authorisation from the US Food and Drugs Administration

Mumbai boosts hospital capacity as Covid cases rise, bed occupancy doubles

Around 10 out of every 1,000 beds are already occupied by Covid-19 patients, up from 4 a week ago

Covid-19 pandemic: Maharashtra, Kerala on high alert as cases spike

On Tuesday, Maharashtra recorded 1,881 new Covid cases, 81 per cent more than the previous day and highest since February 18

Paraguay cancels orders for one million doses of Covaxin, say sources

Media reports cite quality issues; sources say Bharat Biotech had stopped production and exports in April, any pending orders stand cancelled

Price is the key growth driver of Indian pharma market, shows AWACS data

Market set to grow by 2.5-5% in calendar 2022. could even hit 5% due to a strong seasonal sales such as anti-infectives, and impact of NLEM drugs price hike

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta